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Neuropsychiatric manifestations 
of COVID‑19 can be clustered 
in three distinct symptom 
categories
Fatemeh Sadat Mirfazeli1,8, Atiye Sarabi‑Jamab2,8, Amin Jahanbakhshi3, Alireza Kordi4, 
Parisa Javadnia4, Seyed Vahid Shariat1, Oldooz Aloosh5, Mostafa Almasi‑Dooghaee6 & 
Seyed Hamid Reza Faiz7*
Several studies have reported clinical manifestations of the new coronavirus disease. However, few 
studies have systematically evaluated the neuropsychiatric complications of COVID‑19. We reviewed 
the medical records of 201 patients with confirmed COVID‑19 (52 outpatients and 149 inpatients) that 
were treated in a large referral center in Tehran, Iran from March 2019 to May 2020. We used clustering 
approach to categorize clinical symptoms. One hundred and fifty‑one patients showed at least one 
neuropsychiatric symptom. Limb force reductions, headache followed by anosmia, hypogeusia were 
among the most common neuropsychiatric symptoms in COVID‑19 patients. Hierarchical clustering 
analysis showed that neuropsychiatric symptoms group together in three distinct groups: anosmia 
and hypogeusia; dizziness, headache, and limb force reduction; photophobia, mental state change, 
hallucination, vision and speech problem, seizure, stroke, and balance disturbance. Three non‑
neuropsychiatric cluster of symptoms included diarrhea and nausea; cough and dyspnea; and fever 
and weakness. Neuropsychiatric presentations are very prevalent and heterogeneous in patients 
with coronavirus 2 infection and these heterogeneous presentations may be originating from 
different underlying mechanisms. Anosmia and hypogeusia seem to be distinct from more general 
constitutional‑like and more specific neuropsychiatric symptoms. Skeletal muscular manifestations 
might be a constitutional or a neuropsychiatric symptom.
In December 2019 a number of severe acute respiratory syndrome (SARS) were reported in Wuhan, China that 
became eventually a pandemic infection with over 8 million reported cases until June  20201. The typical symp-
toms include fatigue, fever, cough, and diarrhea. The infective agent, a coronavirus SARS-CoV-2, was named 
COVID-19 by World Health Organization (WHO) on 11 February 2020 which is a human coronavirus. Six other 
corona viruses are introduced that are hosted by humans: MERS-CoV, SARS-CoV, HCoV-229E, HCoV-HKU1, 
HCoV-NL63, and HCoV-OC43. COVID-19 is believed to attack respiratory and gastrointestinal systems (GI) 
by attaching to angiotensin-converting enzyme 2(ACE2)  receptors2,3.
It has been documented that the β-coronaviruses like COVID-19 tend to involve the central nervous system, 
mainly brainstem. The ACE2 receptors in the brain are believed to play a  role3,4. A direct route of entry into 
the central nervous system through the olfactory nerve is also  postulated5. This finding is consistent with the 
prevalent and early olfactory symptoms in COVID-196. However, it is not yet clear whether all patients with 
olfactory symptoms would develop neurologic complications, or all patients with neurological complications 
would show olfactory symptoms. Most studies on neurologic manifestations utilized frequency  tests6,7 while using 
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more advanced analysis such as clustering analysis would help us to furtherly categorize the neuropsychiatric 
manifestations.
Neurological manifestations has been reported up to 36% of patients in one study on 214 COVID-positive 
patients in  Wuhan7. Encephalitis and meningitis are also rarely reported as a complication of COVID-198,9. 
However, our knowledge is still scarce regarding characteristics of neurologic symptoms; whether or not they 
could be a sign of more severe case of COVID-19 or there is any correlation with other prognostic biomarkers 
such as lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP)10, or other 
clinical and paraclinical presentations.
Few studies have evaluated the neuropsychiatric manifestations of COVID-19 and to our knowledge; none of 
them have used a statistical clustering method to assess the symptom clusters of these manifestations. Identify-
ing the clusters of related clinical findings is of great importance, because different clusters might be caused by 
distinct underlying mechanisms. Therefore, we decided to investigate the neuropsychiatric findings in COVID-19 
patients by using a hierarchical clustering method in one of the largest referral centers in Iran.
Results
Muscle weakness (60.2%) was the most common symptoms followed by dyspnea (56%), cough (55.2%), and 
fever (51.2%).One hundred and fifty-one patients (75.1%) showed at least one neuropsychiatric symptom. Limb 
force reduction (40.3%), followed by headache (39.8%), anosmia (33.8%), hypogeusia (32.8%) were among the 
most common neuropsychiatric symptoms in COVID-19 patients (Fig. 1).
The relation between the neuropsychiatric manifestations with other clinical symptoms. To 
investigate the clinical symptoms in COVID-19 patients, we used a hierarchical clustering approach for identify-
ing different groups of symptoms. This approach resulted in an attractive tree-based representation of the obser-
vations, called a dendrogram. In this approach each object is initially considered as a single-element cluster, and 
at each step of the algorithm, the two clusters that are the most similar are combined into a new bigger cluster. 
This procedure is iterated until the tree of the cluster is generated. To measure the dissimilarity, we used Gower 
dissimilarity that can be used to calculate the distance between two entities whose attribute has categorical val-
ues. The dissimilarity between two clusters is calculated based on minimizing the total within-cluster variance.
The result of our hierarchical analysis showed that we have six main clusters. Neuropsychiatric symptoms 
grouped together in three distinct groups: anosmia and hypogeusia (olfactory symptoms); dizziness, headache, 
and limb force reduction (general constitutional-like neuropsychiatric symptoms); photophobia, mental state 
change, hallucination, vision and speech problem, seizure, stroke and balance disturbance (specific neuropsy-
chiatric symptoms or specific CNS type). Three non-neuropsychiatric cluster of symptoms included diarrhea 
and nausea (gastrointestinal symptoms); cough and dyspnea (respiratory symptoms); and fever and weakness 
(constitutional symptoms). It seems that the cluster of GI symptoms is completely separated from cluster of 
respiratory symptoms while it is closer to the neurological symptoms (specifically the ones with olfactory and 
general constitutional-like symptoms). However, cluster of constitutional symptoms is closer to the cluster of 
respiratory symptoms. Skeletal muscular manifestations might be a constitutional or a neuropsychiatric symptom.
Figure 2 shows the cluster dendrogram of the clinical symptoms.
Moreover, to visualize clearer, the relation between neuropsychiatric symptoms and other clinical symptoms 
is shown in Fig. 3 as a scatter plot.
Laboratory measure findings in patients with COVID‑19. CBC, LFT, and ABG tests were requested 
for some hospitalized patients and these tests were repeated if necessary, in some cases. To know about the trend 
Figure 1.  The frequency of neuropsychiatric manifestations along with respiratory and gastrointestinal 
symptoms in 201 patients with COVID-19.
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of changing on these tests, we took the average measures based on the number of patients that are tested on that 
iteration. Figure 4A, B, C shows the trend of change in CBC, LFT, and ABG test, respectively.
We also investigated which factors of demographic factors such as age, gender, and clinical presentation 
could be the best predictors of WBC, RBC, and Platelet results. Therefore, we used a stepwise selection method 
to find the best subset of predictors.
The results of linear regression for finding the predictors of WBC count are shown in Table1. These variables 
jointly explain 79% variance of scores,  R2 = 0.79, F (19, 13) = 2.69, P value: 0.03.
The results of linear regression for finding the predictors of SGPT are also shown in Table 1. These variables 
explain 59% variance of scores,  R2 = 0.59, F (10, 27) = 2.69, P-value: 0.02. Furthermore, the results of linear 
regressing for finding the predictors of SGOT shows that only photophobia explains 17% variance of scores, 
R2 = 0.17, F (1, 36) = 2.69, P value: 008, see Table 1.
Discussion
To the best of our knowledge, this study is one of the fewest attempts to explore and categorize neuropsychiatric 
manifestations along with other organ involvements in COVID-19. Hierarchical clustering analysis showed 
that neuropsychiatric symptoms group together in three distinct groups: anosmia and hypogeusia (olfactory 
Figure 2.  Tree-based representation (clustering) of the clinical symptoms in 201 patients with COVID-19 
showing six main clusters: (olfactory symptoms), (general constitutional-like neuropsychiatric symptoms), 
(specific neuropsychiatric symptoms or specific CNS type), (gastrointestinal symptoms), (respiratory 
symptoms), (constitutional symptoms). In this figure the Sequel means seizure and stroke.
Figure 3.  The scatter plot of the relation between neuropsychiatric symptoms and respiratory symptoms, 
gastrointestinal symptoms and constitutional symptoms in 201 patients with COVID-19.
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Figure 4.  The trend of CBC, LFT, and ABG tests on 20 (A,B) and 10 (C) hospitalized patients with COVID-19. 
(A) The trend of CBC factors in 20 patients with COVID-19. The result shows a decrease following the increase 
of PLT count as the disease progresses. (B) The trend of LFT and CPK in 20 patients with COVID-19. There is a 
surge of CPK in the third testing, (C) The trend of ABG factors in 10 hospitalized patients with COVID-19.
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symptoms); dizziness, headache, and limb force reduction (more constitutional-like neuropsychiatric symptoms); 
photophobia, mental state change, hallucination, vision and speech problem, stroke, seizure and balance distur-
bance (more specific neuropsychiatric symptoms or more specific CNS-type). Three non-neuropsychiatric cluster 
of symptoms included diarrhea and nausea (GI symptoms); cough and dyspnea (respiratory symptoms); and 
fever and weakness (constitutional symptoms). It seems that the cluster of GI symptoms is completely separated 
from the cluster of respiratory symptoms while it is closer to neurological symptoms (specifically the ones with 
olfactory and general constitutional-like symptoms). However, cluster of constitutional symptoms is closer to 
the cluster of respiratory symptoms. Having all serious neurological symptoms in one cluster is a probable sign 
for a different type of COVID-19 (maybe specific CNS type).
Neuropsychiatric manifestations were very prevalent among our patients (75.1%). They showed a variety of 
neuropsychiatric complications from limb force reduction (40.3%) and headache (39.8%) as the most common 
symptom and seizure (2%) and stroke (1%) as a rare consequence of COVID-19. These findings are almost in 
line with previous  studies7, however in Ling Mao et al. study, fewer patients (36.4%) were reported to show 
neuropsychiatric  complications7. This discrepancy could be explained by several reasons, one of them might be 
the fact that we had a more comprehensive checklist and we included symptoms such as hallucination, speech 
problems, photophobia in our checklist. The other reason would be Ling Mao et al.7 reported muscle injury while 
we documented decreased muscle force irrespective of the range of CPK. Consistent with the study of Ling Mao 
et al.7 seizure and stroke were one of the rarest presentations in CNS involvement of covid-19. Stroke as a sequel 
of COVID-19 came up in other  studies11, as well. In one study in Italy, they reported a 2.5% ischemic stroke in 
Table 1.  Linear regression analysis showing predictors of WBC count, SGPT, SGOT in 20 patients with 
COVID-19. *p value < 0.05,**p value < 0.01,***p value < 0.001.
Coefficients Estimate std Error t value Pr.( >|t|)
WBC predictors
Intercept 9.81 2.07 4.73 < 0.001***
Gender male − 2.29 1.58 − 1.44 0.17
Onset − 0.20 0.07 − 2.61 0.02*
Dyspnea 3.96 1.56 2.53 0.02*
Cough − 3.66 1.40 − 2.61 0.02*
Nausea − 4.12 1.54 − 2.66 0.01*
Diarrhea 5.77 1.79 3.21 0.006**
Headache 1.38 1.45 0.94 0.36
Balance disturbance − 8.83 2.17 − 4.05 0.001**
Speech problem − 5.90 3.57 − 1.65 0.12
Weakness 2.72 1.42 1.90 0.07
Limb force reduction − 4.01 1.93 − 2.07 0.05
Auditory hallucination − 13.27 3.65 − 3.63 0.003**
Visual hallucination 7.98 4.31 1.85 0.08
Altered mental status 2.54 2.31 1.10 0.29
Sequel (stroke and seizure) − 2.64 2.69 − 0.98 0.34
Anosmia 4.43 1.77 2.50 0.02*
Hypogeusia − 7.28 2.51 − 2.89 0.01*
Vision problem 3.63 2.76 1.31 0.21
Disorientation 14.75 3.20 4.60 < 0.001***
SGPT predictors
Intercept 61.98 15.46 4.008 < 0.001***
Cough − 33.46 17.36 − 1.92 0.06
Fever 46.18 18.24 2.53 0.01*
Balance disturbances − 46.68 26.77 − 1.74 0.09
Limb force reduction − 53.49 20.35 − 2.62 0.01*
Auditory hallucination 178.23 54.28 3.28 0.002**
Visual hallucination − 154.01 60.96 − 2.52 0.01*
Altered mental status − 44.33 28.77 − 1.54 0.13
Anosmia − 105.16 31.11 − 3.38 0.002**
Hypogeusia 110.00 35.90 3.06 0.004**
Disorientation 61.74 39.67 1.55 0.13
SGOT predictors
Intercept 68.11 17.20 3.95 < 0.001***
Photophobia 171.89 61.23 2.80 0.008**
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COVID-19  patients11. In comparison in China among hospitalized COVID-19 patients, this rate was around 
5%12. These slight differences might be due to different sampling, different screening tools, and other meth-
odological distinctions. However, it is not yet explored which patients would present with such serious squeals.
Around 11% of our patients reported visual or auditory hallucination which could be secondary to delirium, 
or neuro-inflammation, both of which are possible based on previous  literature13,14. However, the second one 
seems more probable in our patients because although hallucination and disorientation are in the same clus-
ter, hallucination was closer to other neuropsychiatric presentations rather than disorientation. In Ferrando 
et al. study, psychosis was reported in three alert and oriented patients as a direct result of COVID-19 CNS 
 involvement13.
In 9% of our patient photophobia was detected. Even though photophobia is not a common presentation, 
having it in a cluster with altered mental status and other neurological symptoms can imply the possibility of 
encephalitis or aseptic meningitis. Case reports of encephalitis have been already reported in these  patients15. 
However, other etiologies such as medication side effects for photophobia should be kept in mind.
Altered mental status from disorientation to complete loss of consciousness has been seen in the patients 
which can be caused by several factors such as electrolyte disturbances, hypoxia, delirium, encephalopathy 
and  stroke15. Due to possibility of CNS involvement and multi-organ damage we should consider a list of dif-
ferential diagnosis in approaching the COVID-19 patients with mental status change rather than attributing it 
to just hypoxic encephalopathy. However, our knowledge is still scarce regarding the underlying mechanism of 
mental state change in COVID-19 patients. Different efforts have been made to explain underlying mechanisms 
of mental status changes and other neuropsychiatric presentations of COVID-19. Receptor injury, cytokine 
storm, retrograde travel via nerve fibers, secondary damage due to hypoxia have all been suggested as possible 
 mechanisms9. The COVID-19 virus is believed to attach ACE receptor in GI, in epithelial cells of the lungs, in 
endothelial cells of blood–brain-barriers leading to cytokine release and inflammatory responses in the targeted 
 organs2,3,16–18. This will cause neuro-inflammation along with lung and other organ damages. Alveolar damage 
may further lead to hypoxia and possible ischemic neural damage as a result. It has been also proposed that the 
virus might travel ascendantly via the olfactory bulb to the brain, creating a connection between nasal epithelium 
and central nervous  system19. Accordingly, about one third of the patients presented anosmia and hypogeusia 
but these two symptoms shared a cluster together, rather than with the rest of neurologic symptoms. It may be 
another implication that there is more than one mechanism for CNS involvement (i.e., via retrograde transmis-
sion through olfactory bulb). Yet it is not clear in which patient every one of these mechanisms may activate. 
However, consistent with other  studies20, the rate of anosmia and hypogeusia, were higher than Ling Mao et al. 
 report7. This can be another reason for higher rate of neuropsychiatric manifestations in our findings.
Moreover, skeletal muscular manifestations in COVID-19 clustered in two distinct groups, one was subjec-
tive muscle weakness which clustered with constitutional symptoms of fever and the other was decreased force 
of limbs which clustered with two other neuropsychiatric symptoms (dizziness and headache). It may show two 
distinct underlying mechanisms for neuromuscular manifestations. We also had a surge of CPK in the trend of 
laboratory measure in our findings. However due to small sample size it was not clear which symptoms would 
represent actual muscular injury.
Added to finding the proximity of clinical symptoms, we also found an association between some clinical 
presentations and biomarkers such as WBC, SGPT, and SGOT. In recent articles role of biomarkers such as WBC, 
PLT, lymph count, and IL6 factor in disease risk stratification have been  investigated21.
Finding heterogeneous neuropsychiatric manifestations from mild to severe conditions in a notable pro-
portion of patients necessitates the neuropsychiatric examinations in all COVID-19 patients. Clustering these 
neuropsychiatric presentations in three distinct symptom categories besides providing some possible underlying 
pathophysiological mechanism for the disease, have also the following clinical implications as well:
1. It suggests that in the thorough neuropsychiatric assessment of the patients with COVID-19, all the three 
neuropsychiatric symptom categories should be covered.
2. Importance of each of these categories seems to be different. For example, finding a specific neuropsychiatric 
symptom might be a red flag mandating immediate further investigation such as neuroimaging. However, 
anosmia does not seem to be associated with more grave condition.
3. Patient who has symptoms in different categories might need various treatment options. The more general 
constitutional-like symptom category might only need hydration and resting .The specific neuropsychiatric 
symptom category, however might need aggressive treatment such as  plasmapheresis22 or corticosteroid 
 therapy23.
This study was not without limitations. We should consider that some of these neuropsychiatric presenta-
tions might be due to reasons other than coronavirus 2 such as medication side effect, electrolyte disturbance, 
hypoxia, comorbid diseases. It was a cross-sectional study and only laboratory tests with a clinical indication 
were requested for the patients. Larger sample sizes with larger laboratory measures could show a better picture 
of the disease. Having the genotype of the virus and HLA mapping of the patients in combinations with their 
clinical clustering and para-clinical presentation could help us understand the various behavior of the virus better 
and come closer to find a treatment. Brain imaging in our study was only ordered for critical patients and may 
some patients with stroke gone under diagnosed amid the crisis. Considering COVID-19 virus as a pathogen 
with the possibility of nervous system invasion will help clinicians to suspect COVID-19 in patients with CNS 
symptoms and to avoid misdiagnosis of COVID-19.
Neuropsychiatric presentations are very common and heterogeneous in patients with COVID-19 and should 
be evaluated in patients with COVID-19. These heterogeneous presentations might have different underlying 
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mechanisms. Anosmia and hypogeusia seem to be distinct from two other clusters of neuropsychiatric symptoms, 
i.e., more general constitutional-like symptoms and more specific neuropsychiatric symptoms. Skeletal muscular 
manifestations might be a constitutional or a neuropsychiatric symptom.
Methods
We evaluated 201 participants with a confirmed diagnosis of COVID-19 (52 outpatients and 149 inpatients) 
from March 2019 to April 2020 in a large referral Hospital in Tehran (Rasoul Akram Hospital). Demographic 
characteristics and comorbidities are shown in Table 2. The diagnosis was based on a positive real-time reverse 
transcription-polymerase chain reaction assay using a COVID-19 nucleic acid detection kit or a typical chest 
CT scan for COVID-19 reported by three specialists (an emergency medicine specialist, an infectious disease 
specialist, and a pulmonologist). The diagnosis was supported by related laboratory tests (biochemistry and 
inflammatory factors). Patients were diagnosed with COVID-19 according to WHO interim  guideline24.
All of the patients or the closest available relative gave an informed consent for the study. This research has 
been approved by the ethics committee of the Iran University of Medical Science (code number: IR.IUMS.
REC.1399.080).
Data collection. Those with no or mild symptoms were quarantined at home and were followed to answer 
the online checklist. The follow-up was done by a trained medical student. Patients with moderate to severe 
symptoms were hospitalized and examined daily by a trained neurologic resident. We collected the data from 
conscious cognitively capable patients and their families as well as from the medical team where needed. Then, 
we documented the data including demographics, comorbidities, drug history, neuropsychiatric history, symp-
tomatology of coronavirus infection. History of seizure or stroke during COVID-19 was confirmed by a related 
specialist, if reported. For hospitalized patients, chest CT Scan, laboratory tests including arterial blood gas 
analysis, count blood cell (CBC), liver function test, renal function test, inflammatory markers, creatine phos-
phokinase test (CPK) if requested for the patient were all documented. Criteria for additional laboratory tests 
were saturation sat  O2 < 90%, impaired consciousness, systolic blood pressure < 90 MMHG, medical disease 
comorbidity, deterioration of the course the disease, dehydration and intolerance of oral intake or when neces-
sary to diagnose or follow-up patients, therefore some inpatients did not have all paraclinical data.
Statistical analysis. All statistical analyses were performed using R (version 3.6.1; R Core Team, 2019) in 
RStudio (RStudio-1.2.5001). For numerical variables, we used mean and standard deviation (SD) when they 
were normally distributed and we used range if they were not. Continuous variables were compared by using the 
Wilcoxon rank-sum test.
To perform a cluster analysis in R, we prepared data as rows were observations (individuals) and columns 
were variables, and we removed the missing values. We also used the “StatMatch” package to find the dissimilarity 
matrix, and we used the “cluster” package in clustering algorithms. We used the function “hclust”, and specified 
Table 2.  Demographic characteristics and comorbidities in 201 patients with COVID-19.
Characteristics Total Male Female
Age, mean (SD), year 51.84 (16.57) 51.36 (14.37) 52.54 (15.40)
Weight, mean (SD), kg 76.51 (18.27) 81.42 (20.10) 69.40 (12.2)
Gender, number (percent %) 201 (100%) 119 (59.2%) 82 (40.8%)
Patient status, number (percent %)
Inpatients 142 (70.6%) 86 56
Outpatients 52 (25.9%) 29 23
ICU 7 (3.5%) 4 3
Comorbidity, number (percent%), Yes 107 (53.2%) 53 54
Diabetes mellitus 37 (18.4%) 21 16
Cerebrovascular disease 17 (8.4%) 5 12
Hypertension 28 (13.9%) 16 12
Pulmonary disease 10 (4.9%) 5 5
Renal disease 11 (5.4%) 6 5
Cancer 6 (2.9%) 2 4
Hyperlipidemia 7 (3.4%) 4 3
Endocrine disease 9 (4.4%) 3 6
Hematologic disease 6 (2.9%) 1 5
Rheumatologic disease 6 (2.9%) 1 5
EarNoseThroat disease 5 (2.4%) 3 2
Psychiatric disease 1 (0.49%) 1 0
Neurologic disease 5 (2.4%) 2 3
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the agglomeration method as “ward.D2” method and we plotted the dendrogram (Fig. 2). Finally, we visualized 
the result in a scatter plot by utilizing the “factoextra “package (Fig. 3).
To find the predictor factors in our laboratory measures, we performed the stepwise regression by iteratively 
adding and removing variables in each step. To do this in R, we used “MASS” package, which choose the best 
model based on AIC criterion, and we used “stepAIC” function for stepwise regression (Table 1). The significance 
threshold at a 2-sided P value was set at less than 0.05.
Ethics declarations. Written informed consent was obtained from all of the patients or the closest available 
relative for the study. This research has been approved by the Ethics Committee of the Iran University of Medical 
Science (Code Number: IR.IUMS.REC.1399.080).
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